Table 1.
Patient characteristics
| SA (n=11) | Surgery (n=10) | P-value | |
|---|---|---|---|
| Sex (M/F) | 5/6 | 5/5 | 0.83 |
| Age (years) | |||
| Pre | 52 ± 3.8 | 50 ± 4.9 | 0.72 |
| Post | 53 ± 3.9 | 51 ± 4.7 | 0.73 |
| BMI | |||
| Pre | 28.7 ± 1.6 | 26.9 ± 1.1 | 0.40 |
| Post | 28.6 ± 1.6 | 26.3 ± 1.4 | 0.30 |
| Adenoma size | 0.94 | ||
| Macro | 10 | 9 | |
| Micro | 1 | 1 | |
| GH, nadir (µg/l) | |||
| Pre | 6.3 (2.4; 16.3) | 4.9 (2.2; 10.7) | 0.66 |
| Post | 0.6 (0.2; 1.6)* | 0.4 (0.2; 0.7) | 0.19 |
| IGF-I (µg/l) | |||
| Pre | 739 ± 85 | 649 ±76 | 0.44 |
| Post | 214 ± 35 | 209 ± 25 | 0.91 |
| IGF-ISDS | |||
| Pre | 4.7 ± 0.3 | 4.3 ± 0.5 | 0.46 |
| Post | 1.1 ± 0.5 | 1.2 ± 0.4 | 0.99 |
| Fasting glucose (mmol/L) | |||
| Pre | 5.6 (5.1; 6.1) | 5.9 (5.3; 6.5) | 0.48 |
| Post | 5.7 (5.3; 6.3) | 4.9 (4.4; 5.4) | 0.03 |
| HbA1c (mmol/mol) | |||
| Pre | 40 (35; 45) | 43 (38; 49) | 0.45 |
| Post | 41 (35; 46) | 36 (30; 41) | 0.23 |
| Time btw. study days (weeks) | 58 (16; 163) | 29 (18; 47) | 0.05 |
| Surgery (y/n) | 6/5 | 10/0 | 0.01 |
| Radiation therapy (y/n) | 0/11 | 0/10 | NA |
| Dopamine agonist (y/n) | 1/10 | 1/9 | 0.94 |
| Diabetes mellitus (y/n) | 0/11 | 1/9 | 0.28 |
| Anterior pituitary deficiency (y/n) | 3/8 | 1/9 | 0.70 |
*Exclusion of patients treated with a GH-antagonist
Patient characteristics at time of diagnosis and after disease control according to treatment modality; Somatostatin analogue (SA) and Surgery. Data are presented as total number, mean ± SEM or median (CI) when logarithmically transformed. Time since intervention is presented as mean and range. The two groups were comparable at all listed variables.